## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE TECHNOLOGY APPRAISAL PROGRAMME

## **Equality impact assessment – Scoping**

## STA Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal or gastroesophageal junction cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
n/a	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
n/a	
1	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal or gastroesophageal junction cancer

Issue date: November 2020

No							
_	 _	 	_	_	_		

Approved by Associate Director (name): ......Janet Robertson......

Date: 25 November 2020

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal or gastroesophageal junction cancer

Issue date: November 2020 2 of 2